ClinicalTrials.gg
Enrolling by invitationNCT06369571Updated Oct 19, 2026

Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet

A Phase 1/2 interventional study of Atorvastatin 10mg and Modification of dietary fat composition in Epilepsy and Dyslipidemia, sponsored by Johns Hopkins University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Johns Hopkins University · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Epilepsy by Johns Hopkins University — 2 open to participants now, 3 under way, none of them phase 3. Epilepsy · Johns Hopkins University.

Planned enrollment
7th of 12
22 · median 26
Started
2024
with 1 other
Phase 1/2
Only one
of the 16
Registered
16th of 16
by date

Among the 16 studies in Epilepsy by Johns Hopkins University, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 1/2, and was the 16th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 16 studies in Epilepsy by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Epilepsy by Johns Hopkins University, or all of them as a file.
02

Study summary

Ketogenic diet therapies (KDTs) emphasize high fat and very low carbohydrate intake and help to control seizures in adults who fail to respond to medications. However, KDT use can lead to increased cholesterol levels in some adults with epilepsy (AWE). Treatments that can reverse elevations in cholesterol observed with long-term KDT use without compromising diet adherence and seizure control are needed. The proposed study will explore the feasibility and safety of diet modification and statin use to lower cholesterol in this population. Study findings will help guide doctors utilizing KDTs in adults with epilepsy on how to approach managing elevations in cholesterol.

Read the detailed description

The scientific premise of this proposal is that established or long-term (≥ 12 months) Modified Atkins diet (MAD) use in AWE influences atherosclerotic cardiovascular disease (ASCVD) risk and can be modified to reduce dyslipidemia when observed. Hence, the overarching goals of this proposal are to explore the safety and feasibility of dyslipidemia management strategies to reduce ASCVD risk in AWE on MAD without increasing seizure risk. This study will collect data before and after randomly assigned interventions to reduce LDL in AWE on long-term MAD recruited from patients receiving clinical care in the Johns Hopkins Adult Epilepsy Diet Center.

AWE with dyslipidemia on long-term MAD will be randomized 1:1 to either MAD modification (10% reduction of dietary energy from saturated fat, replaced with poly-unsaturated fat ) or moderate-intensity statin use (atorvastatin 10mg) for 12 weeks.

03

Conditions studied

  • Epilepsy
  • Dyslipidemia

Keywords

  • Modified Atkins Diet
  • Ketogenic Diet
  • Cholesterol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Modified Atkins Diet use ≥ 12 months
  2. Dyslipidemia based on American College of Cardiology/American Heart Association guidelines (i.e., LDL ≥190 mg/dL, 10-year ASCVD risk ≥5% with risk enhancers, etc.)
  3. 18 years of age or older
  4. (BMI) > 18.5
  5. Stable anti-seizure medication regimen for > 1 month.

Exclusion criteria

Exclusion Criteria:

  1. \< 18 years of age
  2. (BMI) \< 18.5
  3. Changes in anti-seizure medication regimen \< 1 month prior to participation
  4. Known ASCVD (history of acute coronary syndrome, myocardial infarction, angina, stroke, , or peripheral artery disease)
  5. Current statin medication use
  6. Prior serious adverse response to atorvastatin or other statin medications
  7. Uncorrected carnitine deficiency
  8. Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
22 participants (estimated)

Study arms

  • Active comparator
    Statin

    Participants will receive 10mg of atorvastatin daily for 12 weeks

    Drug: Atorvastatin 10mg

  • Experimental
    Modified Atkins diet (MAD) Modification

    Participants will be instructed on how to change their modified Atkins diet for 12 weeks. They will replace 10% of daily dietary energy from saturated fat with poly-unsaturated fat.

    Other: Modification of dietary fat composition

Interventions

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atorvastatin 10mg daily by mouth

    Also known as: Lipitor

  • OtherModification of dietary fat composition

    Replace 10% of saturated fat intake with polyunsaturated fat

06

What researchers measure

Primary outcomes

  1. Diet adherence as assessed by 3 day food records

    Diet adherence will be based on the ability to achieve 10% reduction in dietary energy from saturated fat assessed from 3-day food records, the gold standard for diet intake assessments.

    Time frame: 12 weeks

  2. Statin Adherence

    Statin adherence will be determined based on pills returned at study completion, with participants labeled adherent if 80% or more of pills were consumed.

    Time frame: 12 weeks

  3. LDL Change

    12-week % LDL change from baseline within arms and between arms

    Time frame: 12 weeks

  4. Change in weekly seizure frequency

    12-week difference in weekly seizure frequency from baseline

    Time frame: 12 weeks

  5. Seizure severity questionnaire score

    12-week difference in seizure severity questionnaire (SSQ) score (score 1-7, with higher score indicating more severe seizures)

    Time frame: 12 weeks

Secondary outcomes

  1. Frequency of adverse events

    Frequency of adverse events

    Time frame: 12 weeks

  2. Blood ketone change

    12-week difference in serum beta-hydroxybutyrate level from baseline

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Jun 2028, 44 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Jan 2027 → Jun 2028 and completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 17, 2024
StartActual
Oct 4, 2024
Primary completionEst.
Jun 2028was Jan 2027
CompletionEst.
Dec 2028was Dec 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2027→Jun 2028
Oct 19, 2026
Study completion
Dec 2027→Dec 2028
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Jan 2027→Jun 2028
    Study completion Dec 2027→Dec 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06369571
Collaborators
American Heart Association
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Oct 4, 2024
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Tanya J McDonald, MD, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion